Montreal start-up CogniSens has developed promising new technology to quickly and accurately assess concussions in athletes. If evaluation of the technology over the next six months goes well, sports clubs could be able to accurately diagnose concussions better than ever before.
CogniSens has two main technologies to offer sports teams.
One is a system called the NeuroMinder, which can accurately measure mild perceptual impairment in a four-minute visual test.
The test results can be compared with the athlete’s normal neural acuity to assess how far the recovery has come.
The technology will be validated over the next six months at five medical research centres, including Toronto’s Baycrest Centre for research on aging and the brain.
The idea is to find out whether it can be used to also help people with Alzheimer’s, disease, early childhood learning disability or driving impairment.
The other product is a three-dimensional “cave” called the NeuroTracker, in which athletes can improve their performance through perceptual and cognitive training. Improved reaction times can help them avoid future injury.
For example, they are asked to track the movement of four balls on a screen, in a fast-moving field of other balls. This test can also measure whether a concussed athlete’s cognitive performance is back to game shape.
The Gazette reports that several NHL teams are using the technology, as well as two English Premier League teams. Also, as mentioned in the article, the technology has more potential applications than detecting concussions; it can be used to diagnose cognitive impairment in the elderly, dementia patients, and CogniSens is even promoting the technology to police forces to help them nad impaired drivers.
For more information on CogniSens, click here.